Showing 841-850 of 1043 results for "".
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/30981/Eli Lilly Implements Transparent Physician Payment PolicyEli Lilly has announced a pioneering initiative to enhance transparency in its financial interactions with healthcare professionals. Starting in the latter half of 2009, Lilly will publicly disclose payments exceeding $500 made to physicians f
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31013/Editorial Insight: Navigating Healthcare Policy ChallengesIn the June 2008 issue of *Practical Neurology*, Editor-in-Chief Jack Persico addresses the tumultuous landscape of healthcare policy amidst economic instability. Highlighting the volatile oil prices and their ripple effects on the stock mark
- Small change: Can income growth offset a shrinking dollar?https://practicalneurology.com/columns/practice-management/small-change-can-income-growth-offset-a-shrinking-dollar/31015/Annual Income Survey Highlights Ongoing Economic Challenges for NeurologistsThe seventh annual income survey conducted by Practical Neurology reveals persistent economic challenges faced by neurologists, underscoring a troubling "perfect storm" of factors negatively impacting their practice. Over se
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31020/Recent advancements in stroke prevention highlight the critical role of rapid intervention following transient ischemic attacks (TIAs). Two pivotal studies, EXPRESS and SOS-TIA, provide robust evidence supporting immediate evaluation and treatment to significantly reduce the risk of subsequent strok
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31047/Recent advancements in Transient Ischemic Attack (TIA) management have been the focus of numerous publications, highlighting the critical need for updated approaches in clinical practice. A comprehensive meta-analysis encompassing 11 natural history studies with 7,238 patients underscores the elevat
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31062/Practical Neurology continues to serve as a vital resource for healthcare professionals in the neurology field, emphasizing both clinical excellence and effective practice management. In the January 2008 issue, Editor-in-Chief Jack Persico highlights the critical importance of communication between
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31087/Establishing a successful hospital-based stroke program critically depends on unwavering support from hospital administration, a key requirement for Joint Commission on Accreditation of Healthcare Organizations (JCAHO) primary stroke center certification. In his December 2007 article for Practical N
- What Should We Do About Asymptomatic AVMs?https://practicalneurology.com/columns/practice-management/what-should-we-do-about-asymptomatic-avms/31127/Clinical Decision-Making in the Management of Asymptomatic Cerebral Arteriovenous MalformationsCerebral arteriovenous malformations (AVMs) present a significant clinical challenge, especially when asymptomatic. The primary dilemma revolves around balancing the natural hemorrhage risk against the pot
- Levodopa: Life Begins at 40?https://practicalneurology.com/columns/practice-management/levodopa-life-begins-at-40/31189/Levodopa Remains Cornerstone in Parkinson’s Disease Therapy After 40 YearsForty years after the seminal 1967 Cotzias study, levodopa continues to be the primary treatment for Parkinson’s disease (PD), underscoring its enduring efficacy in managing motor symptoms. Levodopa’s journey from a laboratory
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31187/Levodopa’s Enduring Role in Parkinson’s Disease Management: A Reflective AnalysisAs the medical community commemorates the 40th anniversary of the Cotzias study, which revolutionized Parkinson’s disease (PD) treatment with the introduction of levodopa, its sustained prominence remains a topic of sig